

Shuta Ohara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6778786/publications.pdf>

Version: 2024-02-01

21
papers

497
citations

1040056

9
h-index

839539

18
g-index

21
all docs

21
docs citations

21
times ranked

597
citing authors

#	ARTICLE	IF	CITATIONS
1	Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	19
2	Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations. <i>Cells</i> , 2021, 10, 354.	4.1	9
3	The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. <i>Surgery Today</i> , 2021, 51, 1480-1487.	1.5	5
4	Activity of tarloxotinib in cells with EGFR exon 20 insertion mutations and mechanisms of acquired resistance. <i>Thoracic Cancer</i> , 2021, 12, 1511-1516.	1.9	15
5	Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. <i>Lung Cancer</i> , 2021, 154, 84-91.	2.0	9
6	KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1321-1332.	1.1	118
7	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3659-3670.	2.8	7
8	Intra-tumor and inter-tumor heterogeneity in MET exon 14 skipping mutations and co-mutations in pulmonary pleomorphic carcinomas. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	0
9	In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. <i>Lung Cancer</i> , 2021, 162, 79-85.	2.0	1
10	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. <i>Lung Cancer</i> , 2020, 148, 100-104.	2.0	6
11	Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer. <i>Surgery Today</i> , 2020, 50, 1427-1433.	1.5	11
12	Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study. <i>Translational Lung Cancer Research</i> , 2020, 9, 1915-1923.	2.8	34
13	Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1753-1765.	1.1	105
14	Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. <i>Surgical Case Reports</i> , 2019, 5, 105.	0.6	1
15	Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis. <i>Surgery Today</i> , 2019, 49, 513-520.	1.5	3
16	P2.17-41 Treatment Outcomes of Pulmonary Resection in NSCLC Patients with Autoimmune Diseases. <i>Journal of Thoracic Oncology</i> , 2019, 14, S901.	1.1	0
17	P2.01-37 Lower Risk of Hypercoagulability in Non-Small Cell Lung Cancer Patients with EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, S653.	1.1	0
18	EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, 727-731.	1.1	39

#	ARTICLE	IF	CITATIONS
19	Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer, 2018, 126, 149-155.	2.0	40
20	Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer, 2018, 126, 72-79.	2.0	59
21	Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer, 2017, 112, 57-61.	2.0	16